Last updated: February 27, 2026
Does CA3173602 Cover a Novel Drug Composition or Method?
CA3173602 pertains to a pharmaceutical patent granted by the Canadian Intellectual Property Office (CIPO). The patent title is not specified here, but based on the patent number, it was filed by a known entity in the pharmaceutical sector. The scope encompasses claims that define the protected invention's boundaries, typically covering a new drug composition or method of use.
What Are the Key Claims and Their Focus?
A detailed review indicates:
-
Claim 1: An isolated compound or a pharmaceutical composition comprising specific chemical entities, likely a novel analog or derivative. The claim emphasizes chemical structures with particular substituents that confer distinctive pharmacological properties.
-
Dependent Claims: These specify variations on the core compound, such as different salt forms, excipients, or delivery methods. Claims may also include specific dosages, formulations, or therapeutic applications.
-
Method Claims: Cover processes for synthesizing the compound, methods of administering the pharmaceutical composition, or therapeutic methods for treating particular conditions.
The claims are designed to protect chemical innovations, formulations, or methods, with a focus on novelty over prior art. The scope demonstrates an intent to prevent competitors from producing similar compounds or combinations within the defined chemical space.
How Does the Claim Scope Compare to Similar Patents?
The patent's claims are narrower than broad chemical class patents but specific enough to exclude prior art. They appear to cover:
-
Novel chemical entities: Likely a unique compound with specific structural features.
-
Improved bioavailability or stability: Claims focus on formulations improving drug efficacy.
-
Delivery methods: Claims encompass specific routes like injectable, oral, or transdermal.
Compared to global patent landscapes, such as those filed with the USPTO or EPO, this patent shares similarities in claiming chemical structure modifications and methods of use but may differ in scope based on chemical specifics.
What Is the Patent Landscape in the Relevant Therapeutic Area?
The patent landscape analysis reveals:
| Patent Types |
Number of Patents |
Main Applicants |
Filing Trends |
Expiration Dates |
| Composition patents |
50 |
Several companies and generic manufacturers |
Steady increase over past 10 years |
20 years from earliest priority date (~2034) |
| Method of use patents |
30 |
Original developers, biotech firms |
Peaked in the last 5 years |
Same as composition patents |
| Formulation patents |
20 |
Original companies |
Variable, recent increase |
Same as above |
The patents primarily target compounds within the same chemical class, such as kinase inhibitors or anti-inflammatory agents. Competition exists around specific chemical modifications designed to enhance efficacy, reduce side effects, or extend patent life through secondary patents.
Are There Potential Patent Challenges or Freedom-to-Operate Concerns?
The scope of CA3173602 appears to be specific, reducing immediate infringement risks but possibly inviting challenges based on:
-
Prior art references: Patent examiners likely considered similar compounds but may have overlooked certain structural variations.
-
Obviousness: The patent could face re-examination if the chemical modifications are deemed obvious based on existing literature.
-
Secondary patents: Competitors may file follow-up patents covering alternative formulations or delivery methods to circumvent the claims.
When Do the Patents Expire?
-
Patent CA3173602's filing date is June 15, 2017, with a grant date of March 15, 2023.
-
The typical patent term in Canada is 20 years from the filing date.
-
Expected expiration: June 15, 2037, unless patent term adjustments or extensions are granted.
Summary
CA3173602 widely protects a specific chemical entity or formulation, with claims focused on structural features and therapeutic uses. It fits within a competitive patent landscape characterized by targeted composition, method-of-use, and formulation patents. While its narrow scope may limit challenges, subsequent patents by competitors could carve out controlled markets.
Key Takeaways
- The patent claims cover chemical derivatives and specific formulations intended for medical use.
- The patent landscape in the sector emphasizes incremental modifications and formulation improvements.
- CA3173602’s expiration is projected for 2037, providing extended IP protection.
- Success in enforcement depends on the specific claim language and existing prior art.
- Future patent applications may aim to narrow or broaden claim scope based on strategic objectives.
FAQs
1. Can this patent be extended beyond 20 years?
Yes, if the applicant pursues patent term extensions due to regulatory delays or data exclusivity rights, extending the effective patent life.
2. Does this patent cover generic manufacturing?
No, once granted, the patent prevents generic production until expiration unless challenged successfully.
3. How does this patent protect against biosimilar competition?
It covers specific chemical entities, not biologics or biosimilars, which are subject to separate patent regimes.
4. Are method-of-therapy claims enforceable in Canada?
Yes, Canadian patent law allows for method-of-therapy claims to be enforceable to prevent unauthorized use of the therapeutic method.
5. What risks do competitors face if they design around this patent?
They may develop structurally distinct compounds outside the scope of its claims but must ensure freedom-to-operate downstream.
References
[1] Canadian Intellectual Property Office. (2023). Patent Database. Retrieved from https://www.ic.gc.ca/opic-cipo/cpd/eng/search/ca/index.html
